Brugada syndrome precipitated by uncomplicated malaria treated with dihydroartemisinin piperaquine: a case report.
Antimalarial drug
Arrhythmia
Brugada syndrome
Electrocardiogram
Heart disease
Malaria
Journal
Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802
Informations de publication
Date de publication:
17 Sep 2024
17 Sep 2024
Historique:
received:
12
02
2024
accepted:
28
08
2024
medline:
18
9
2024
pubmed:
18
9
2024
entrez:
17
9
2024
Statut:
epublish
Résumé
Cardiovascular events following anti-malarial treatment are reported infrequently; only a few studies have reported adverse outcomes. This case presentation emphasizes cardiological assessment of Brugada syndrome, presenting as life-threatening arrhythmia during anti-malarial treatment. Without screening and untreated, this disease may lead to sudden cardiac death. This is a case of 23-year-old male who initially presented with palpitations followed by syncope and shortness of breath with a history of malaria. He had switched treatment from quinine to dihydroartemisinin-piperaquine (DHP). Further investigations revealed the ST elevation electrocardiogram pattern typical of Brugada syndrome, confirmed with flecainide challenge test. Subsequently, anti-malarial treatment was stopped and an Implantable Cardioverter Defibrillator (ICD) was inserted. Another possible cause of arrhythmic events happened following anti-malarial consumption. This case highlights the possibility of proarrhytmogenic mechanism of malaria infection and anti-malarial drug resulting in typical manifestations of Brugada syndrome.
Sections du résumé
BACKGROUND
BACKGROUND
Cardiovascular events following anti-malarial treatment are reported infrequently; only a few studies have reported adverse outcomes. This case presentation emphasizes cardiological assessment of Brugada syndrome, presenting as life-threatening arrhythmia during anti-malarial treatment. Without screening and untreated, this disease may lead to sudden cardiac death.
CASE PRESENTATION
METHODS
This is a case of 23-year-old male who initially presented with palpitations followed by syncope and shortness of breath with a history of malaria. He had switched treatment from quinine to dihydroartemisinin-piperaquine (DHP). Further investigations revealed the ST elevation electrocardiogram pattern typical of Brugada syndrome, confirmed with flecainide challenge test. Subsequently, anti-malarial treatment was stopped and an Implantable Cardioverter Defibrillator (ICD) was inserted.
CONCLUSIONS
CONCLUSIONS
Another possible cause of arrhythmic events happened following anti-malarial consumption. This case highlights the possibility of proarrhytmogenic mechanism of malaria infection and anti-malarial drug resulting in typical manifestations of Brugada syndrome.
Identifiants
pubmed: 39289709
doi: 10.1186/s12936-024-05099-3
pii: 10.1186/s12936-024-05099-3
doi:
Substances chimiques
artenimol
6A9O50735X
Antimalarials
0
piperaquine
A0HV2Q956Y
Artemisinins
0
Quinolines
0
Piperazines
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
283Informations de copyright
© 2024. The Author(s).
Références
Brugada R, Campuzano O, Sarquella-Brugada G, Brugada J, Brugada P. Brugada syndrome. Methodist Debakey Cardiovasc J. 2014;10:25–8.
pubmed: 24932359
pmcid: 4051330
doi: 10.14797/mdcj-10-1-25
Khawaja M, Qadeer YK, Siddiqui R, Chelu MG, Aiumtrakul N, Pickett JK, et al. Brugada syndrome within Asian populations: state-of-the-art review. Cardiogenetics. 2023;13:61–74.
doi: 10.3390/cardiogenetics13020007
Gupta S, Gazendam N, Farina JM, Saldarriaga C, Mendoza I, López-Santi R, et al. Malaria and the heart: JACC state-of-the-art review. J Am Coll Cardiol. 2021;77:1110–21.
pubmed: 33632486
doi: 10.1016/j.jacc.2020.12.042
Kusano KF. Brugada syndrome: recent understanding of pathophysiological mechanism and treatment. J Arrhythmia. 2013;29:77–82.
doi: 10.1016/j.joa.2012.12.009
Chan XHS, Win YN, Haeusler IL, Tan JY, Loganathan S, Saralamba S, et al. Factors affecting the electrocardiographic QT interval in malaria: a systematic review and meta-analysis of individual patient data. PLoS Med. 2020;17: e1003040.
pubmed: 32134952
pmcid: 7058280
doi: 10.1371/journal.pmed.1003040
Chan XHS, Win YN, Mawer LJ, Tan JY, Brugada J, White NJ. Risk of sudden unexplained death after use of dihydroartemisinin-piperaquine for malaria: a systematic review and Bayesian meta-analysis. Lancet Infect Dis. 2018;18:913–23.
pubmed: 29887371
pmcid: 6060085
doi: 10.1016/S1473-3099(18)30297-4
Saadeh K, Nantha Kumar N, Fazmin IT, Edling CE, Jeevaratnam K. Anti-malarial drugs: mechanisms underlying their proarrhythmic effects. Br J Pharmacol. 2022;179:5237–58.
pubmed: 36165125
doi: 10.1111/bph.15959
Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome: a multicenter report. J Am Coll Cardiol. 1992;20:1391–6.
pubmed: 1309182
doi: 10.1016/0735-1097(92)90253-J
Fadilah I, Djaafara BA, Lestari KD, Fajariyani SB, Sunandar E, Makamur BG, et al. Quantifying spatial heterogeneity of malaria in the endemic Papua region of Indonesia: analysis of epidemiological surveillance data. Lancet Reg Health Southeast Asia. 2022;5:100051.
pubmed: 37383667
pmcid: 10305992
doi: 10.1016/j.lansea.2022.100051
Nishizaki M, Yamawake N, Sakurada H, Hiraoka M. ECG interpretation in Brugada syndrome. J Arrhythmia. 2013;29:56–64.
doi: 10.1016/j.joa.2013.01.001
Sieira J, Brugada P. The definition of the Brugada syndrome. Eur Heart J. 2017;38:3029–34.
pubmed: 29020354
doi: 10.1093/eurheartj/ehx490
Amir M, Kabo P, Rahma I. Provocative testing using low dose oral flecainide for diagnosis of Brugada syndrome: a report of two cases. Eur Heart J Case Rep. 2022;6:ytac460.
pubmed: 36751482
pmcid: 9897198
doi: 10.1093/ehjcr/ytac460
Haeusler IL, Chan XHS, Guérin PJ, White NJ. The arrhythmogenic cardiotoxicity of the quinoline and structurally related antimalarial drugs: a systematic review. BMC Med. 2018;16:200.
pubmed: 30400791
pmcid: 6220451
doi: 10.1186/s12916-018-1188-2
Lazzerini PE, Abbate A, Boutjdir M, Capecchi PL. Fir(e)ing the rhythm: inflammatory cytokines and cardiac arrhythmias. JACC Basic Transl Sci. 2023;8:728–50.
pubmed: 37426535
pmcid: 10322731
doi: 10.1016/j.jacbts.2022.12.004
Blok M, Boukens BJ. Mechanisms of arrhythmias in the Brugada Syndrome. Int J Mol Sci. 2020;21:7051.
pubmed: 32992720
pmcid: 7582368
doi: 10.3390/ijms21197051
Cader A, Singh SM, Zia MI. Brugada syndrome unmasked by malaria-induced fever. J Cardiol Cases. 2018;18:136–7.
pubmed: 30279931
pmcid: 6149654
doi: 10.1016/j.jccase.2018.06.002
Meggiolaro M, Zorzi A, Maghawry M, Peruzza F, Migliore F, Pittoni GM. Brugada ECG disclosed by acute malaria: is it all about fever and propofol? J Clin Anesth. 2013;25:483–7.
pubmed: 23999240
doi: 10.1016/j.jclinane.2013.02.012
Tisdale JE, Chung MK, Campbell KB, Hammadah M, Joglar JA, Leclerc C, et al. Drug-induced arrhythmias: a scientific statement from the American heart association. Circulation. 2020;142:e214–33.
pubmed: 32929996
doi: 10.1161/CIR.0000000000000905
Andorin A, Gourraud JB, Mansourati J, Fouchard S, Le Marec H, Maury P, et al. The QUIDAM study: hydroquinidine therapy for the management of Brugada syndrome patients at high arrhythmic risk. Heart Rhythm. 2017;14:1147–54.
pubmed: 28411139
doi: 10.1016/j.hrthm.2017.04.019
Jeong HK, Hong SN, Yoon N, Lee KH, Park HW, Cho JG. Antiarrhythmic effect of artemisinin in an ex-vivo model of Brugada syndrome induced by NS5806. Korean Circ J. 2023;53:239–50.
pubmed: 37161682
pmcid: 10172200
doi: 10.4070/kcj.2022.0312
Borsini F, Crumb W, Pace S, Ubben D, Wible B, Yan GX, et al. In vitro cardiovascular effects of dihydroartemisin-piperaquine combination compared with other anti-malarials. Antimicrob Agents Chemother. 2012;56:3261–70.
pubmed: 22391528
pmcid: 3370756
doi: 10.1128/AAC.05688-11
Kim MS, Kim NY, Park JE, Nam SH. Ventricular arrhythmia in patients with prolonged QT interval during liver transplantation: two cases report. Korean J Anesthesiol. 2014;67:416–20.
pubmed: 25558343
pmcid: 4280480
doi: 10.4097/kjae.2014.67.6.416
Belhassen B. Management of Brugada syndrome 2016: should all high risk patients receive an ICD?. Alternatives to implantable defibrillator therapy for Brugada syndrome. Circ Arrhythm Electrophysiol. 2016;9: e004185.
pubmed: 27906651
doi: 10.1161/CIRCEP.116.004185
Priori SG, Wilde AA, Horie M, Cho Y, Behr ER, Berul C, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm. 2013;10:1932–63.
pubmed: 24011539
doi: 10.1016/j.hrthm.2013.05.014
Brodie OT, Michowitz Y, Belhassen B. Pharmacological therapy in Brugada syndrome. Arrhythm Electrophysiol Rev. 2018;7:135.
pubmed: 29967687
pmcid: 6020192
doi: 10.15420/aer.2018.21.2
Peltenburg PJ, Hoedemaekers YM, Clur SA, Blom NA, Blank AC, Boesaard EP, et al. Screening, diagnosis and follow-up of Brugada syndrome in children: a Dutch expert consensus statement. Neth Heart J. 2023;31:133–7.
pubmed: 36223066
doi: 10.1007/s12471-022-01723-6